Compounded GLP-1 cost calculator

The compounding landscape in 2026

Compounded semaglutide and tirzepatide emerged in 2023 as a telehealth response to the FDA’s drug-shortage listings for Ozempic, Wegovy, Mounjaro, and Zepbound. Under section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed pharmacies can compound a “copy” of a commercially available drug when it appears on the FDA shortage list, typically at a fraction of the branded price. Hims, Ro, Henry Meds, Mochi, and dozens of independent 503A pharmacies built that market.

The landscape changed dramatically in late 2024 and through 2025. In October 2024 the FDA declared the tirzepatide shortage resolved, triggering a wind-down for 503A compounders (60 days) and 503B outsourcing facilities (90 days), subsequently extended by litigation. In February 2025 the FDA declared the semaglutide shortage resolved, with similar wind-down windows. Eli Lilly and Novo Nordisk have since pursued aggressive enforcement against “personalized” dosing claims and online sellers. Legitimate 503A pharmacies still compound GLP-1s when a patient-specific clinical need justifies it — allergy to a branded excipient, a dose strength not commercially available, or combination therapy — but the economics and legal risk have shifted significantly. Always verify your source.

Typical price points (ballpark, 2026)

Compounded semaglutide via established telehealth: $199–$399/month depending on dose and provider. Compounded tirzepatide: $249–$499/month. These prices usually include the telehealth visit and shipping. Compare against:

• Wegovy pen list price: roughly $1,349/month at AWP. Insurance copay varies wildly — $25 with a good commercial plan and the Wegovy savings card, $300–$600 on a high-deductible plan, denied entirely on most Medicare and many Medicaid plans.
• NovoCare self-pay (Wegovy vial): approximately $499/month for the single-dose vial delivered via NovoCare® Pharmacy. This is the manufacturer’s cash-pay answer to compounded semaglutide.
• Ozempic retail cash: roughly $999–$1,529/month with GoodRx coupons at large chain pharmacies.
• Zepbound pen list price: approximately $1,086/month. With commercial coverage and the Lilly savings card, copays commonly run $25 for covered patients and $550 for non-covered.
• LillyDirect self-pay vials (Zepbound): $349–$499/month for 2.5, 5, 7.5, or 10 mg vials shipped direct. (See our LillyDirect tool.)
• Mounjaro retail cash: around $1,000–$1,135/month with coupons.

The headline savings — compounded sema at $299 vs Wegovy list at $1,349 — is real on paper. The savings against the manufacturer’s self-pay vial programs (NovoCare at $499, LillyDirect at $349–$499) are much narrower and often not worth the regulatory and quality-control tradeoff. That is the comparison the chart above forces you to make.

503A vs 503B: why it matters

The FDA regulates two categories of compounding pharmacies:

• 503A pharmacies: traditional compounders, state-licensed. They compound patient-specific prescriptions. Quality standards follow USP <797> (sterile) and USP <795> (non-sterile). The FDA does not inspect most 503A pharmacies unless a complaint triggers action. Most telehealth GLP-1s are 503A.
• 503B outsourcing facilities: FDA-registered, inspected under cGMP, can produce non-patient-specific batches. Much higher quality bar, higher cost, and most 503B facilities exited the GLP-1 market after the shortage declarations.

Verify any pharmacy filling your prescription through the NABP’s Verified-Accredited Wholesale Distributor program and through your state board of pharmacy. Reject any operation that cannot produce a state license number, a pharmacist-in-charge name, and a certificate of analysis (COA) for the active pharmaceutical ingredient batch your vial came from.

What you are actually buying when you buy “compounded semaglutide”

A compounded sterile injection is the active pharmaceutical ingredient (API) — semaglutide base or tirzepatide base — reconstituted in bacteriostatic water or another FDA-recognized diluent, at a concentration specified on the prescription. Several practical concerns:

• Salt forms: the FDA has explicitly stated that compounded GLP-1s must use the same base molecule as the approved drug. Some pharmacies have used semaglutide sodium or semaglutide acetate salts with unclear bioequivalence. This is a red flag. Ask for the base form.
• API sourcing: most compounders source API from Chinese or Indian manufacturers. Quality varies. Demand a COA that shows ≥99% purity, endotoxin testing, and impurity profiling.
• Concentration and fill volume: a 5 mL vial at 10 mg/mL gives you 50 mg semaglutide — enough for 20 weeks at 2.5 mg/week (a non-label “microdose” scheme) or about 10 weeks at the labeled Wegovy 2.4 mg ceiling if used as intended. Different pharmacies use different concentrations; this matters when you read dosing instructions.
• Additives: some compounders add B12 (“sema + B12”) or NAD+ precursors. These are marketing additions with no evidence of improved weight outcomes. Pure API is preferable.

Dose strengths — what compounders can and cannot replicate

Branded Wegovy ships as five pre-filled pens at 0.25, 0.5, 1.0, 1.7, and 2.4 mg. Zepbound ships at 2.5, 5, 7.5, 10, 12.5, and 15 mg. Compounded pharmacies typically dispense multi-dose vials at a single concentration (commonly 10 mg/mL semaglutide or 5 mg/mL tirzepatide), leaving the patient to draw the correct number of units with an insulin syringe. This has two consequences: (a) dosing errors are more common than with pens (a Reddit community analysis counted over 200 self-reported 10× overdose events in 2023–2024 from misreading unit marks), (b) intermediate and micro-doses not commercially available (e.g., tirzepatide 3 mg weekly for sensitive patients, semaglutide 0.1 mg for ultra-low maintenance) become possible. For trial-comparable efficacy, use the standard labeled dose ladder — STEP 1 and SURMOUNT-1 efficacy numbers apply only at those label doses.

Insurance, HSA, and FSA treatment

Compounded GLP-1s are almost never covered by commercial insurance because they are not FDA-approved products. Your PBM will reject the claim. HSAs and FSAs, however, generally do reimburse compounded prescriptions when a licensed clinician has written the script for a qualifying medical purpose (obesity, type 2 diabetes). Keep the prescription, the pharmacy receipt, and an SOAP note on file in case of audit. See the HSA/FSA calculator for the tax-adjusted savings.

How much clinical efficacy do you trade for the cost savings?

No randomized trial has compared compounded product to branded in a head-to-head design. What we have is: (a) the efficacy of branded product in STEP 1 (14.9% TBWL, semaglutide 2.4 mg, 68 weeks), SURMOUNT-1 (22.5% TBWL, tirzepatide 15 mg, 72 weeks), SURMOUNT-5 (direct sema-vs-tirz comparison), and SELECT (20% MACE reduction); (b) manufacturer testing reports of compounded samples showing 50–80% label potency variance; (c) community-reported TBWL on compounded that clusters 20–40% below trial mean at comparable nominal doses. Extrapolating to a cost-per-pound basis: $299/mo compounded at 65% relative efficacy produces roughly 22 lb in 12 months — cost-per-pound ~$163. $499 branded via LillyDirect at full trial-comparable efficacy produces ~35 lb — cost-per-pound ~$171. The gap closes once you adjust for response. See the cost-per-pound calculator.

How to run the math honestly

Here is the comparison most patients should run, not “compounded vs brand list price”:

1. Your insured copay on Wegovy or Zepbound, if covered. With the manufacturer savings cards, many commercial patients pay $0–$25/month. That beats compounded on pure cost and wins decisively on quality.
2. NovoCare at $499 or LillyDirect at $349–$499, if not covered. These are the manufacturer’s answer to compounded. Paying $200 more per month for FDA-approved product is usually the right call.
3. Compounded at $249–$399, if the above are unavailable or unaffordable. The only scenario where the math truly favors compounding is uninsured patients who cannot qualify for the Novo or Lilly patient assistance programs, or patients whose PA has been repeatedly denied.

See the generic vs brand tool for a deeper side-by-side and the monthly budget calculator to see how the compounded price fits into your all-in cost.

FAQ

Is compounded semaglutide bioequivalent to Wegovy?

There is no FDA-required bioequivalence testing for compounded products — the FDA does not approve them. Pharmacokinetic studies on compounded sema are scarce. Assume they work similarly if the API is genuine and correctly dosed, and plan to confirm response with the scale, waist tape, and your clinician. If you are not seeing trial-comparable TBWL by month 4 on a therapeutic dose, switch to the branded product.

Does my HSA cover compounded tirzepatide?

Generally yes, if your HSA custodian accepts prescription receipts from a licensed pharmacy. The IRS defines eligible medical expenses broadly; a prescribed compounded medication for an obesity diagnosis qualifies. Save the prescription, the receipt, and the pharmacy’s state license number.

Will my prescriber keep writing compounded scripts after the shortage ends?

Many will not. The legal landscape is narrow: 503A compounding is permitted for patient-specific reasons other than cost (allergy to an excipient, a strength not commercially made). Some telehealth platforms have pivoted to NovoCare/LillyDirect referral or hybrid models.

Why is compounded cheaper than the branded drug if the molecule is the same?

Research, development, clinical trials, FDA approval, post-marketing safety studies, and marketing cost Novo Nordisk and Lilly billions. Compounding pharmacies shoulder none of those costs. They also carry no reimbursement contracts, no manufacturer rebates, no DTC advertising, and no cardiovascular outcomes trial (SELECT, SUMMIT) overhead. That explains the price gap — and explains why the FDA’s approval process matters for long-term safety.

How do I spot an unsafe compounded seller?

Red flags: (1) no physician visit before prescribing, (2) no state pharmacy license on the website or an out-of-country pharmacy, (3) peptide sold “for research purposes only” with a wink, (4) prices under $100/month (below API cost), (5) promises of “weekly microdose kits” or Ozempic-plus-something cocktails, (6) no COA on request.

Related tools

• Generic vs brand GLP-1 — full side-by-side comparison
• LillyDirect cost calculator — self-pay Zepbound vials
• HSA/FSA GLP-1 savings — pre-tax dollar arithmetic
• Monthly budget calculator — all-in cost with visits and labs